SCHEMBL25351372

SCHEMBL25351372

Cc1ccccc1-c1nc(NS(=O)(=O)c2ccccc2)cc(Cl)c1C(F)(F)F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 5/20 0.42
▸ ALDH1A1 P00352 4/20 0.42
▸ HSD17B10 Q99714 4/20 0.42
▸ HPGD P15428 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ ALOX15 P16050 3/20 0.41
▸ HTT P42858 2/20 0.41
▸ PKM P14618 2/20 0.41
▸ POLB P06746 2/20 0.41
▸ LMNA P02545 2/20 0.41
▸ SYK P43405 1/20 0.41
▸ TSHR P16473 2/20 0.40
▸ HSD11B1 P28845 1/20 0.40
▸ MEN1 O00255 3/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ SDHB P21912 1/20 0.40
▸ FFAR4 Q5NUL3 1/20 0.39
▸ SCN9A Q15858 1/20 0.39
▸ MCL1 Q07820 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25352596 0.86 PIK3CD (0.39) HTTPOLBLMNAHSD11B1MEN1
SCHEMBL25351134 0.76 BRD4 (0.42) GAAALDH1A1HSD17B10HPGDKDM4E
SCHEMBL25351414 0.75 SDHB (0.38) ALDH1A1KDM4EHTTPOLBLMNA
SCHEMBL25351896 0.73 GABRP (0.40) HTTHSD11B1SDHB
SCHEMBL29515284 0.73 KDM4E (0.46) ALDH1A1KDM4EPOLBSYKTSHR
SCHEMBL26797318 0.72 KDM4E (0.51) GAAALDH1A1HSD17B10HPGDKDM4E
SCHEMBL8657978 0.70 LMNA (0.50) GAAALDH1A1HSD17B10HPGDALOX15
SCHEMBL19925056 0.70 SCN9A (0.44) ALDH1A1KDM4ELMNAHSD11B1MEN1
SCHEMBL29464473 0.70 SCN9A (0.44) ALDH1A1KDM4ELMNAHSD11B1MEN1
SCHEMBL29464506 0.70 SDHB (0.34) HTTPOLBLMNATSHRHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373939-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMA (US) 2023-11-23 — — US disclosed
US-20230373939-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMA (US) 2023-11-23 — — US disclosed
US-20230373939-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMA (US) 2023-11-23 — — US disclosed
EP-4225737-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2023-08-16 — — EP disclosed
WO-2022076628-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373939-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B GAA 1285/4885ALDH1A1 3668/4885HSD17B10 2767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback